Stock Market News2 months Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study Zacks
INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
XINCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.
X